Cost & Savings
If you have:
You could pay:
Commercial Insurance (Usually provided by an employer)
$20.00 or less per dose, depending on state plan.
Medicaid Part D
$851.00 - $3,102.00‡ per dose, depending on coverage phase.
‡Represents catastrophic phase SKYRIZI cost.
Out-of-pocket cost for SKYRIZI may vary depending on patient’s other medication costs.
Most Medicare patients have standard Part D prescription coverage, which has different costs depending on deductibles and coverage gaps. An Insurance Specialist can help you understand what these costs mean to you, by calling 1.866.SKYRIZI (1.866.759.7494).
Medicare Low Income Subsidy (LIS)
$9.85 per dosing starting January 1, 2022.
*Important details about understanding your individual costs:
The chart above provides cost information based on what a person with the type of coverage listed may pay for one (1) 150mg/mL dose of SKYRIZI, which is generally every 3 months. Your type of health or prescription insurance plan will determine exactly how much you will pay. Information listed is accurate as of January 2022 and is based on publicly available benefit design information for Medicaid and Medicare Part D out-of-pocket costs for 2022 plan year.
†Eligible, commercially insured patients may pay as little as $5 for each SKYRIZI starter dose and following quarterly doses.
Terms and Conditions apply. This benefit covers SKYRIZI® (risankizumab-rzaa). Eligibility: Available to patients with commercial prescription insurance coverage for SKYRIZI who meet eligibility criteria. Co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government-funded healthcare program, patient will no longer be able to use the Skyrizi Complete Savings Card and patient must call Skyrizi Complete at 1.866.SKYRIZI to stop participation. Patients residing in or receiving treatment in certain states may not be eligible. Patients may not seek reimbursement for value received from the Skyrizi Complete program from any third-party payers. Offer subject to change or discontinuance without notice. Restrictions, including monthly maximums, may apply. Patients who are members of insurance plans that claim to reduce or eliminate their patients' out of pocket co-pay, co-insurance, or deductible obligations for certain prescription drugs based upon the availability of, or patient's enrollment in, manufacturer sponsored co-pay assistance for such drugs (often termed "maximizer" programs) will have an annual maximum program benefit of $6,000.00 per calendar year. This assistance offer is not health insurance. To learn about AbbVie’s privacy practices and your privacy choices, visit www.abbvie.com/privacy.html